Please use this identifier to cite or link to this item:
|Title:||Clinical safety and recent patents on fixed-dose combinations of DPP-4 inhibitors: An updated review|
|Abstract:||Type 2 diabetes mellitus (T2DM) is the epidemic metabolic disorder with rising globally incidence. The dipeptidyl peptidase- 4 inhibitor (DPP-4I) is a newer class of anti-diabetic drugs showing a conceptual alteration in management of glycemic control by treating fundamental pathophysiological processes instead of a gluco-centric approach. DPP-4I reduced risk of hypoglycemia and weight gain in T2DM patient. Clinical studies revealed that DPP-4Is are safe and effective in T2DM patient and did not increase cardiovascular risk. This review focuses on recent patents (2015-2019) in DPP-4I containing pharmaceutical formulation. Various inventor and companies were pursued in developing fixed-dose combination (FDC) of DPP-4I with metformin or HMG Co-A reductase inhibitors. The present review also describes patented technology for chewable and effervescent dosage form of DPP-4I. � 2020 Plant Archives. All rights reserved.|
|Appears in Collections:||Journals|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.